HT29, a colon adenocarcinoma cell line with a P53 mutation, has been used to study the synergistic effects of AZD1775, a WEE1 inhibitor, combined with chemotherapeutic agents. This evidence concerns the gene WEE1 and colon adenocarcinoma.